CEO pay benchmark · $2B – $10B
Mid-cap Biological Products, (No Diagnostic Substances) CEO salary
The median CEO compensation at mid-cap companies in the biological products, (no diagnostic substances) industry is $10,696,847. That is 20% lower than the median across all biological products, (no diagnostic substances) companies in our benchmark.
Median CEO pay
$10.7M
Typical range
$7.1M–$13.6M
Companies
6
Average pay ratio
Not available
Vs. full industry
-20%
Size effect
How this group compares with the full industry
The same compensation measures are shown side by side, so the company-size difference is visible without mixing in another dataset.
| Measure | Mid-cap | All Biological Products, (No Diagnostic Substances) |
|---|---|---|
| Companies | 6 | 17 |
| Median CEO pay | $10,696,847 | $13,448,935 |
| Average CEO pay | $11,849,921 | $15,494,357 |
| Middle 50% range | $7.1M–$13.6M | $8.2M–$23.2M |
| Average pay ratio | Not available | 24:1 |
Company appendix
Highest CEO pay in this peer group
Up to ten of the highest-paid CEOs in this benchmark, ordered by total annual compensation. Open any company for its full pay breakdown.
| Company | CEO | Total compensation | Market cap |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO | Helen I. Torley | $23.2M | $9.3B |
| Vaxcyte, Inc.PCVX | Grant E. Pickering | $14.5M | $7.6B |
| Vericel CorpVCEL | Dominick Colangelo | $11.2M | $2.4B |
| ADMA BIOLOGICS, INC.ADMA | Adam S. Grossman | $10.2M | $2.1B |
| REPLIGEN CORPRGEN | Olivier Loeillot | $6.1M | $8.0B |
| Cidara Therapeutics, Inc.CDTX | Jeffrey Stein | $6.0M | $7.0B |
Nearby peer groups